3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
84
Neoplasm Metastasis
8
Neoplasms
6
Sarcoma
4
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Untreated Operable Early Breast Cancer
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Somatostatinoma
1
Solid Tumors
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Squamous Cell Lung Carcinoma
1
Rectal Neoplasms
1
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
palbociclib
×
Clear all
NCT04494958
2025-03-24
PALBOBIN
Fundacion Oncosur
Phase 1/2
Completed
24 enrolled
10 charts